Consortia of living bacteria useful for treatment of colorectal cancer

A method of treating colorectal cancer (CRC) and/or intestinal microbiome dysbiosis related to CRC treatment comprising the administration of a composition comprising viable, live bacteria strains (i), intermediate metabolites (ii), end metabolites (iii), and a dispersing medium (iv), wherein said bacteria strains (i) are selected from:

• (A1) strains consuming sugars, fibers, and resistant starch, producing formate and acetate, and being selected from the genera Ruminococcus, Clostridium, Dorea and Eubacterium, optionally selected from the genera Ruminococcus, Dorea and Eubacterium;
• (A2) strains consuming sugars, starch and acetate, producing formate and butyrate, and being selected from the genera Faecalibacterium, Roseburia, Eubacterium and Anaerostipes, optionally selected from the genera Faecalibacterium, Roseburia and Anaerostipes;
• (A3) strains consuming sugars and oxygen, producing lactate, and being selected from the genera Lactobacillus, Streptococcus, Escherichia, Lactococcus and Enterococcus;
• (A4) strains consuming sugars, starch, and carbon dioxide, producing lactate, formate and acetate, and being selected from the genera Bifidobacterium and Roseburia;
• (A5) strains consuming lactate or proteins, producing propionate and acetate, and being selected from the genera Clostridium, Propionibacterium, Veillonella, Coprococcus and Megasphaera;
• (A6) strains consuming lactate and starch, producing acetate, butyrate and hydrogen, and being selected from the genera Eubacterium, Clostridium and Anaerostipes;
• (A7) strains consuming sugar, starch, and formate, producing lactate, formate and acetate, and being selected from the genera Collinsella and Roseburia;
• (A8) strains consuming succinate, producing propionate and acetate, and being selected from the genera Phascolarctobacterium, Flavonifractor and Dialister;
• (A9) strains consuming sugars, fibers, formate and hydrogen, producing acetate and optionally butyrate and being selected from the genera Acetobacterium, Blautia, Clostridium, Moorella, Eubacterium, Methanobrevibacter, Methanomassiliicoccus and Sporomusa;
• and
• optionally (A10) strains consuming sugars, fibers, and resistant starch, producing succinate, and being selected from the genera Alistipes, Bacteroides, Blautia, Barnesiella, Clostridium, Ruminococcus and Prevotella, optionally selected from the genera Alistipes, Bacteroides, Blautia, Clostridium, Ruminococcus and Prevotella;
• wherein said bacteria strains are in each case identified through classification of the full 16S gene with assignment for the different taxonomic levels Phylum:
• 75%, Class:
• 78.5%, Order:
• 82%, Family:
• 86.5%, Genus:
• 94.5%, sequence similarity;
• wherein bacteria strains (i) of all nine groups (A1) to (A9) are present and bacteria strains of group (A10) are optionally present;
• wherein said bacteria strains (i) are present in a total concentration of over 109 bacteria per ml composition;
• and have a viability of over 50% as determined by flow cytometry;
• wherein said intermediate metabolites (ii) are selected from:
• succinate in an amount of less than 5 mM, formate in an amount of less than 5 mM, and lactate in an amount of less than 5 mM;
• wherein said end metabolites (iii) are selected from:
• acetate in an amount of at least 10 mM, propionate in an amount of at least 2 mM, and butyrate in an amount of at least 2 mM;
• and
• wherein said dispersing medium (iv) is selected from:
• culture media, cryoprotecting media, aqueous gels, and polymeric supports.